Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2015

View Archived Issues

Sanofi compares SAR-366234 to latanoprost in patients with glaucoma or ocular hypertension

FDA gives orphan drug status to udenafil for the treatment single ventricle congenital heart disease

Wistar Institute and Spark Therapeutics to study liver-directed gene therapy vectors

Nivolumab gets FDA orphan drug designation for the treatment of HCC

AstraZeneca licenses Starpharma's dendrimer-based drug delivery technology

Caenorhabditis elegans used to model weight gain resulting from antipsychotic use

Cellectis and MD Anderson Cancer Center form collaboration for liquid tumor immunotherapy

OICR and SGC investigators make OICR-9429 available to research community

Cytori stem cell therapy ECCS-50 enters phase III trial in male urinary incontinence

Protalex set to open enrollment in phase I/II study of PRTX-100 for ITP

VCP-746, a cardioprotective adenosine receptor agonist

Basilea Pharmaceutica's BAL-30072 will be part of European iABC program

Cipla EU to acquire two generic businesses in U.S.

Pfizer acquires Hospira

Novel SLC22A5 gene mutation linked to ADHD

Vernalis launches Tuzistra XR in U.S.

Piramal discloses GPR120 agonists

Bristol-Myers Squibb introduces new HIV integrase inhibitors

Novita Pharmaceuticals and Cornell University report fascin inhibitors

Roche patents V1a receptor antagonists

Debiopharm and Solid Biosciences collaborate to investigate alisporivir in DMD

Novel BET inhibitors designed for treating brain cancer

Achillion presents complement factor D inhibitors

European ADAPT SMART initiative launched to improve efficiency in drug development

Second unsolicited offer to acquire InSite Vision deemed superior to QLT's amended proposal

Phase I results for carfilzomib-vorinostat combination in relapsed or refractory B-cell lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...